3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
23
Neoplasm Metastasis
10
Stomach Neoplasms
5
Colorectal Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Esophageal Neoplasms
3
Brain Neoplasms
3
Adenocarcinoma
3
Triple Negative Breast Neoplasms
2
Recurrence
2
Neoplasms
2
Meningeal Carcinomatosis
2
HER2-positive Breast Cancer
2
Breast Cancer With Brain Metastasis
2
Unresectable Locally Recurrent Breast Cancer
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neoplasm, Residual
1
Inflammatory Breast Neoplasms
1
HER2-negative Breast Cancer
1
HER2-mutant Non-Small Cell Lung Cancer
1
HER2-low Hormone Receptor Positive Breast Cancer
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Gastric Adenocarcinoma
1
Colonic Neoplasms
1
Carcinoma
1
Interventions
Oxaliplatin
146
Fluorouracil
137
Capecitabine
122
Leucovorin
106
Irinotecan
85
Radiotherapy
67
Bevacizumab
64
Cetuximab
46
Folfox protocol
28
Surgical Procedures, Operative
23
Radiation
23
Drug Therapy
22
Panitumumab
19
XELOX
18
Chemotherapy, Adjuvant
15
Neoadjuvant Therapy
14
Radiotherapy, Intensity-Modulated
13
Chemoradiotherapy
13
Magnetic Resonance Spectroscopy
11
regorafenib
10
Nivolumab
10
Floxuridine
10
sintilimab
8
raltitrexed
8
Specimen Handling
8
IFL protocol
8
Celecoxib
8
Biopsy
8
trifluridine tipiracil drug combination
7
tislelizumab
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Rectal Neoplasms
×
trastuzumab deruxtecan
×
Clear all
NCT07407465
2026-02-17
CHIMERA
Gruppo Oncologico del Nord-Ovest
Phase 2
Recruiting
42 enrolled